-
Afternoon Market Top Percentage Gainers and Losers (CAAS, GENE, HNSN, SYMX, TPX, SCOK, QXM, IDIX, AIB, HERO)
Friday, April 8, 2011 - 1:58pm | 291Best 1) China Automotive Systems (NASDAQ: CAAS): Skyrocketing 36.49% to $11.14 after reporting that preliminary Q4 sales were ahead of consensus estimates. Looks like a short squeeze is underway. 2) Genetic Technologies (NASDAQ: GENE): Currently up 22.6% to $3.25. Shares have been surging since...
-
Active Screen - CANSLIM: Top 8 for April 8th
Friday, April 8, 2011 - 11:01am | 1150There was no change at the top for the eight stocks ranked by Market Cap: Apple (AAPL), Vale S.A. (VALE), Free McMoran (FCX), Barrick Gold (ABX), Baidu (BIDU), Research in Motion (RIMM), Cognizant Technlogy (CTSH), and Intuitive Surgical (ISRG). The Screener setup was as follows: Last weeks tepid...
-
BIOLASE Technology to Raise $1.80M From Institutional Investors at $5.60 per Share
Friday, April 8, 2011 - 10:15am | 71BIOLASE Technology, Inc. (NASDAQ: BLTI) announced today that it has executed an agreement for the sale of 320,000 shares of its common stock at $5.60 per share to institutional investors in a registered direct offering for approximately $1.80 million in gross proceeds. The offering is expected to...
-
MAKO Surgical Hits 52-Week High (MAKO)
Friday, April 8, 2011 - 10:06am | 34MAKO Surgical (NASDAQ: MAKO) has hit a 52-week high in today's trading. At last check the year-to-date performance of MAKO Surgical has been a gain of 72%.
-
BSD Medical Q2 EPS Loss of $0.05/Share (BSDM)
Friday, April 8, 2011 - 9:04am | 18BSD Medical Q2 EPS Loss of $0.05 per Share (NASDAQ: BSDM)
-
Wedbush Lowers Estimates On Quidel
Friday, April 8, 2011 - 9:04am | 105According to Wedbush, Quidel (NASDAQ: QDEL) estimates are lowered for tapered March flu sales. Wedbush reported that it is lowering its 1Q11 revenue forecast by $2 MM and raising full-year G&A by roughly $2 MM to reflect higher bonus accrual and stock comp given the lack of 2010 bonus accrual...
-
Antares Pharma Trading Higher Pre-Market (AIS)
Friday, April 8, 2011 - 8:14am | 45Antares Pharma (NYSE: AIS) is trading higher today pre-market, after its NDA filing for a new drug was accepted by the FDA. At the time of posting, shares of NDA were trading at $1.83, up 7.65% from Thursday's close.
-
Benzinga's Top Downgrades (MASI, BKE, TGT, COST)
Friday, April 8, 2011 - 8:10am | 132Masimo Corporation (NASDAQ: MASI) was downgraded by BMO Capital from "outperform" to "market perform." MASI's shares closed at $34.11 yesterday. Masimo's trailing-twelve-month revenue is $405.41 million. KeyBanc downgraded Buckle Inc (The) (NYSE: BKE) from “buy” to “hold.” BKE's stock closed at $...
-
Invacare Amends Credit Pact (IVC)
Friday, April 8, 2011 - 8:07am | 14Invacare amends credit pact (NYSE: IVC).
-
Antares Pharma Announces FDA Acceptance of Anturol NDA for Filing
Friday, April 8, 2011 - 8:04am | 90Antares Pharma, Inc. (NYSE: AIS) today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder was accepted for filing for review by the U.S. Food and Drug Administration. Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology. The FDA has...
-
Antares Pharma Announces FDA Acceptance For Filing (AIS)
Friday, April 8, 2011 - 8:01am | 19Antares Pharma Announces FDA Acceptance For Filing On Anturol (NYSE: AIS)
-
Wunderlich Securities Initiates Coverage Of Medtronic With Buy Rating
Friday, April 8, 2011 - 7:28am | 149According to Wunderlich Securities, Medtronic (NYSE: MDT) coverage is initiated with a Buy rating. Wunderlich Securities reported that it is initiating coverage of Medtronic, Inc. (MDT) with a Buy rating and a $46 target. “MDT remains the world's largest pure-play medical device company, with...
-
Wunderlich Initiates Coverage on Medtronic With Buy Rating and $46 PT
Friday, April 8, 2011 - 6:37am | 24Wunderlich Securities has initiated coverage on Medtronic (NYSE: MDT) with a Buy rating and $46 price target.
-
Top 4 NYSE Stocks In The Drug Delivery Industry With The Highest Revenue (HSP, VRX, ELN, KV-A)
Friday, April 8, 2011 - 12:17am | 121Below are the top drug delivery stocks on the NYSE in terms of revenue. The trailing-twelve-month revenue at Hospira Inc (NYSE: HSP) is $3.92 billion. HSP's ROE for the same period is 12.30%. The trailing-twelve-month revenue at Valeant Pharmceutical International Inc (NYSE: VRX) is $1.18 billion...
-
GenesisPlus Receives FDA Clearance for Onychomycosis (CUTR)
Thursday, April 7, 2011 - 4:31pm | 164Cutera (NASDAQ: CUTR) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its GenesisPlus. The complete list of the indications for use can be found in the FDA 510(k) clearance number (K) 103626. Known medically as onychomycosis, nail fungus often causes the toenails to...